Consistently, analysis of intratumoral immune cells from BP-sgSTING tumors revealed that, compared to the control group, CD8+ T cell infiltration, anti-tumor cytokine production by CD8+ T cells, and the proportion of effector CD8+ T cells were significantly increased by combined treatment with olaparib and IP injection of DMXAA (Supplementary Fig. 6c), suggesting that a systemically delivered STING agonist was able to activate and mobilize host immune cells to exert anti-tumor immunity. The gene discussed is STING1; the disease is neoplasm.